Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Risk-reducing salpingo-oophorectomy (RRSO) is recommended for BRCA1/2 mutation carriers because of their increased risk of ovarian carcinoma.
|
29315498 |
2018 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Women with an existing breast carcinoma diagnosis who are found to carry a BRCA1/2 mutation have a substantial risk of developing both a contralateral breast carcinoma and ovarian carcinoma.
|
11900216 |
2002 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
One mutation and three rare variants were identified in four women with no family history of breast or ovarian carcinoma whereas all women with affected first-degree relatives did not harbor BRCA1 mutations.
|
10951344 |
2000 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germ-line mutations in the BRCA1 and BRCA2 genes confer a predisposition to breast as well as ovarian carcinoma.
|
9661879 |
1998 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in Scotland.
|
9155062 |
1997 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
It is not yet known how frequently somatic BRCA1 mutations predispose to breast and ovarian carcinoma in the general female population.
|
8173065 |
1993 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
|
28882436 |
2017 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To compare BRCA1 mutations in papillary serous carcinoma of the peritoneum and papillary serous ovarian carcinoma.
|
9764635 |
1998 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
|
31653147 |
2019 |
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Reduced BRCA1 gene expression is common in the sporadic form of ovarian carcinoma.
|
23339184 |
2013 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Alteration of expression of the tumor suppressor gene BRCA-1 has been widely studied in breast and ovarian carcinoma.
|
30446260 |
2019 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Eligible patients are premenopausal BRCA1/2 mutation carriers after completing childbearing without (a history of) ovarian carcinoma.
|
26286255 |
2015 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
At the time of salpingo-oophorectomy, five of 58 BRCA1 carriers (8.6%) were diagnosed with an occult carcinoma: two fallopian tube carcinomas, two ovarian carcinomas and one case was defined as a fallopian tube/ovarian carcinoma.
|
15083174 |
2004 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We propagated a novel BRCA1-null human ovarian cancer cell line UWB1.289 from a tumor of papillary serous histology, the most common form of ovarian carcinoma.
|
17259345 |
2007 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRCA1/2 pathogenic (P) and likely pathogenic (LP) germline variants are frequent among patients with ovarian carcinoma.
|
30606148 |
2019 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The similar frequency distribution of BRCA1/2 mutations in PPC and OvC observed in the present study indicates that these mutations may predispose to PPC as well and that this neoplasm is part of the hereditary breast-ovarian cancer syndrome.
|
12504628 |
2003 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRCA2 mutations were less common than BRCA1 mutations in families with any history of ovarian carcinoma.
|
10717622 |
2000 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study shows that BRCA1 IHC is well correlated with molecular events in ovarian carcinoma.
|
23232854 |
2013 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A high proportion of young women with invasive OC have mutations in BRCA1, and a smaller fraction have mutations in other known OC genes.
|
26718727 |
2016 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRCA-1 and BRCA-2 are tumor suppressor genes in familial breast-ovarian carcinoma syndrome.
|
11550149 |
2001 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
|
10880552 |
2000 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Multiple mechanisms cause nearly universal dysfunction of BRCA1 and/or BRCA2 in hereditary and sporadic ovarian carcinoma.
|
12237285 |
2002 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
|
29855141 |
2018 |
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The identification of germ-line mutations in 2 genes (BRCA1 and BRCA2) responsible for the majority of hereditary ovarian cancers has led an increasing number of women carriers of these mutations to undergo prophylactic oophorectomy (PO) to reduce their risk of subsequent ovarian carcinoma.
|
17001151 |
2006 |
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we show that the p53-related gene p73, encoding a proapoptotic protein that is linked to chemosensitivity in many settings, is upregulated through a novel epigenetic mechanism in both human and murine models of BRCA1-associated ovarian carcinoma.
|
20807817 |
2010 |